BioSpace News Archive

Predicine Corporation, a global molecular insights company, announced the appointment of Linh H. Le as its new Chief Financial Officer.

CytoDyn Inc. today announced that the U.S. District Court for the District of Maryland has granted CytoDyn’s previously-announced motion for a preliminary injunction against NSF International, Inc. and its subsidiary Amarex Clinical Research (“Amarex”), the Company’s former Contract Research Organization (“CRO”).

Fibroblast activation protein is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents.

Patient tracking is a sophisticated process designed to monitor patient’s movements, outside conventional clinical settings such as hospitals, clinics, diagnostic center and laboratories.

Decongestants are widely used in the treatment of nasal congestion. They are also used for relieving systems associated with hay fever, sinusitis, and colds and flu.

Alzheimer’s disease is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment.

American CryoStem Corporation a clinical-stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and therapies announced that its clinical study team has completed recruiting subjects for its Investigational New Drug Phase I Clinical Trial for Post-concussion syndrome.

Pfizer Inc. announced an additional agreement with the United Kingdom government to supply an additional 2.5 million treatment courses of its investigational candidate PAXLOVID™, subject to local authorization.

Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU.

Sorriso Pharmaceuticals, a company focused on transforming anti-inflammatory antibody therapy, announced the company has closed on a $31 million Series A financing.